Thus far, evidence supporting the use of immune checkpoint inhibitors (ICIs) is most abundant in cases of metastatic treatment-refractory cases of gastric cancer and hepatocellular carcinoma;6,7 what has made those approvals interesting is that the response rate has been independent of biologic marker status, such as microsatellite instability-high (MSI-H) or programmed cell death-ligand 1 (PD-L1) expression. This evidence concerns the gene CD274 and gastric cancer.